IDH1 and glioblastoma: IDH-mutant, 1p/19q-codeleted tumors (oligodendrogliomas) may achieve median survival exceeding 14 years, whereas those with IDH wildtype low-grade tumors often demonstrate rapid progression and poor prognosis analogous to primary glioblastoma [2,3].